Board of Directors

J. Stark Thompson, Ph.D.
Chairman of the Board

Dr. Thompson is the former President and CEO of Life Technologies Inc. (now Invitrogen). Dr. Thompson has over thirty years of experience in life sciences technology development and commercialization. From 1988 to 2000, Dr. Thompson served as President and Chief Executive Officer of Life Technologies Inc. and was on the Executive Committee of its largest shareholder Dexter Corporation. Prior to joining Life Technologies, Dr. Thompson served in multiple positions of increasing responsibility over a period of 21 years at DuPont de Nemours and Co., a diversified chemical company. Dr. Thompson held numerous positions at DuPont de Nemours and Co. such as Business Director of the Clinical Systems Division, Manager of the Instruments Systems Division and Manager of Health Care Business Planning. Dr. Thompson received his B.S. in Chemistry from Muskingum College and Ph.D. in Physiological Chemistry from Ohio State University. Dr. Thompson is currently a member of the executive committees of several educational and non-profit organizations and serves as a member of the Board of Directors of Luminex (Nasdaq:LMNX) and Chairman of the Board of GeneLogic (Nasdaq:GLGC)


Will Brooke

William W. Brooke is Managing Partner of Harbert Venture Partners and oversees Harbert's Life Science investments. He also is a Partner of the Harbinger/Aurora Venture Funds, and has served on their Investment Committee and Members' Advisory Committee. Mr. Brooke has been advising start-up companies for more than twenty years, and currently serves on the boards of AV Holdings (Atherotech), Emageon and MaxCyte. As EVP and board member of Harbert for over ten years, Mr. Brooke initially served as the firm's General Counsel and later as its Chief Operating Officer. Mr. Brooke is a guest lecturer on venture capital at the MBA programs at the University of Alabama and the University of Alabama in Birmingham. Mr. Brooke holds degrees in Law and Business Management from the University of Alabama.


Douglas A. Doerfler
President and CEO

Douglas Doerfler joined MaxCyte as its founding President and CEO in June 1999 and has served as a Director since December 1999. Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology holding company (Novagen, Pel-Freez Clinical Systems, and Pel-Freez Biological). From May 1994 until May 1996 he was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. From 1981 until 1994, Mr. Doerfler held various executive positions with Life Technologies Inc. and its predecessor company, Bethesda Research Laboratories. At Life Technologies, Mr. Doerfler was Director of Corporate Development and World Wide Director of Instrumentation and Apparatus responsible for the company's global sequencing and separation business, including electroporation. Mr. Doerfler received his B.S. in Finance from the University of Baltimore School of Business and a certificate in Industrial Relations. He serves on the Biotechnology Industry Organization's Board of Directors, Executive Committee of the Emerging Company Section Board of Governors and the Health Section Governing Body as well as currently serving as a Director for the Maryland High Technology Council and as a Vice Chair for MdBio.


Stanley Erck

Mr. Erck, President and CEO, and Director of IOMAI Corporation, applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept and Integrated Genetics) to shepherd the development and commercialization of IOMAI technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through IPO. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.


Chris Hegele

Chris Hegele joined Intersouth Partners in 2003. He is a long standing member of the Southeast's venture capital community, having spent nearly 20 years as a general partner with Kitty Hawk Capital, a venture capital firm located in Charlotte, North Carolina. Kitty Hawk was founded in 1980 and manages $100 million in four venture capital funds. Prior to joining Kitty Hawk in 1984, Chris was with Arthur Andersen & Co. in its Small Business Group.


Arthur M. Mandell

Mr. Mandell joined Prestwick in November 2005 and serves as President and Chief Operating Officer. Mr. Mandell has also served as a Director of the Company since October 2005. Mr. Mandell has over 25 years of healthcare management experience in both the pharmaceutical and biotechnology sectors, with extensive expertise in business development, strategic planning, product development, and commercialization of products and services. Most recently, Mr. Mandell was President, Chief Executive Officer, and a Director of Cellective Therapeutics, Inc., a Maryland-based monoclonal antibody company which was acquired by MedImmune Inc. in October, 2005. Prior to joining Cellective, Mr. Mandell was President, Chief Executive Officer, and still serves as a Director of Stemron Corporation, a therapeutic stem cell start up company in Gaithersburg, Maryland. Prior to joining Stemron Corporation, Mr. Mandell served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. (HGS), in Gaithersburg, Maryland. He was instrumental in aiding HGS' transition from an early stage drug discovery company to a fully integrated biopharmaceutical company. Mr. Mandell began his career in California, where he spent over 13 years in various leadership positions, both domestic and international, at Syntex Corporation in Palo Alto, California. Before the merger of Syntex Corporation and F. Hoffman-La Roche, Mr. Mandell was responsible for the Pacific Sector including all Far East Operations as well as Canada and Mexico. He also has experience in the pharmaceutical/biotechnology service sector in his capacity as Partner and West Coast General Manager for ZS Associates, a healthcare consulting firm headquartered in Evanston, Illinois. Mr. Mandell currently serves as a Director for the Maryland High Technology Council and as a Director for the MdBio organization.


David Pierson

David Pierson brings 12 years of pharmaceutical industry experience to Intersouth Partners, where he works with the life science investment team. David joined Intersouth in early 2005 from New Jersey-based NPS Pharmaceuticals, where he built and launched the company's first specialty field sales organization. Prior to NPS, he was director of global marketing for Pharmacia Corporation's oncology franchise, managing the company's portfolio of branded oncology drugs in Europe and Latin America. He began his pharmaceutical career at Johnson & Johnson, advancing through a variety of sales and marketing management roles from managing sales territories to evaluating in-licensing and acquisition opportunities to launching marketing plans for new drugs in the U.S. David holds a B.S. from the United States Military Academy and an M.B.A. from Duke University.


A. Sinclair Dunlop

Mr. Dunlop has almost two decades of international experience in evaluating early-stage biotechnology companies. As the Founder and Managing Partner of MASA Life Science Ventures he leads the review and analysis of Fund investment candidates. A former international business and economics analyst with the Center for Strategic & International Studies in Washington, D.C., Mr. Dunlop has private equity and venture capital experience in East Asia, Europe, the U.S. and Israel. Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also holds an M.A. with Honors in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Mr. Dunlop currently serves on the Boards of Engene Inc., Mediquest Therapeutics Inc., MaxCyte Inc. and Potentia Pharmaceuticals Inc.